PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and Their Future Perspectives

World Health Organization Top 10 causes of death., Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index2.html(Accessed on: January 4 2022)

World Economic Forum and Harvard School of Public Health The global economic burden of Noncommunicable Diseases., 2011. Available from: http://www3. weforum.org/docs/WEF_Harvard_ HE_GlobalEconomicBurdenNonCommunicableDiseases_2011.pdf(Accessed on: January 5, 2022).

Benhuri, B.; Ueyama, H.; Takagi, H.; Briasoulis, A.; Kuno, T. PCSK9 inhibitors and ezetimibe monotherapy in patients not receiving statins: A meta-analysis of randomized trials. Curr. Vasc. Pharmacol., 2021, 19(4), 390-397.
[http://dx.doi.org/10.2174/1570161118666200807114559] [PMID: 32767943]

Wierzbicki, A.; Graham, C.; Young, I.; Nicholls, D. Familial combined hyperlipidaemia: under - defined and under - diagnosed? Curr. Vasc. Pharmacol., 2008, 6(1), 13-22.
[http://dx.doi.org/10.2174/157016108783331268] [PMID: 18220935]

Ali, A.H.; Younis, N.; Abdallah, R.; Shaer, F.; Dakroub, A.; Ayoub, M.A.; Iratni, R.; Yassine, H.M.; Zibara, K.; Orekhov, A.; El-Yazbi, A.F.; Eid, A.H. Lipid-lowering therapies for atherosclerosis: Statins, fibrates, ezetimibe and PCSK9 monoclonal antibodies. Curr. Med. Chem., 2021, 28(36), 7427-7445.
[http://dx.doi.org/10.2174/0929867328666210222092628] [PMID: 33655822]

Béliard, S.; Carreau, V.; Carrié, A.; Giral, P.; Duchêne, E.; Farnier, M.; Ferrières, J.; Fredenrich, A.; Krempf, M.; Luc, G.; Moulin, P.; Bruckert, E. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: Can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis, 2014, 234(1), 136-141.
[http://dx.doi.org/10.1016/j.atherosclerosis.2014.02.021] [PMID: 24637413]

Mundal, L.; Sarancic, M.; Ose, L.; Iversen, P.O.; Borgan, J.K.; Veierød, M.B.; Leren, T.P.; Retterstøl, K. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992-2010 J. Am. Heart Assoc, 2014, 3(6), e001236.
[http://dx.doi.org/10.1161/JAHA.114.001236] [PMID: 25468658]

Vishwakarma, V.K.; Upadhyay, P.K.; Gupta, J.K.; Yadav, H.N. Pathophysiologic role of ischemia reperfusion injury: A review. J. Indian Coll. Cardiol., 2017, 7(3), 97-104.
[http://dx.doi.org/10.1016/j.jicc.2017.06.017]

Maurya, K.; Semwal, B.C.; Singh, N.; Khatoon, R.; Paswan, S.; Debjit, B. Chronopharmacology: As a therapy for cardiovascular disease. Pharma Innov., 2012, 1(3), 6-15.

Seidah, N.G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov., 2012, 11(5), 367-383.
[http://dx.doi.org/10.1038/nrd3699] [PMID: 22679642]

Abifadel, M.; Varret, M.; Rabès, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; Derré, A.; Villéger, L.; Farnier, M.; Beucler, I.; Bruckert, E.; Chambaz, J.; Chanu, B.; Lecerf, J.M.; Luc, G.; Moulin, P.; Weissenbach, J.; Prat, A.; Krempf, M.; Junien, C.; Seidah, N.G.; Boileau, C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003, 34(2), 154-156.
[http://dx.doi.org/10.1038/ng1161] [PMID: 12730697]

Cohen, J.; Pertsemlidis, A.; Kotowski, I.K.; Graham, R.; Garcia, C.K.; Hobbs, H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet., 2005, 37(2), 161-165.
[http://dx.doi.org/10.1038/ng1509] [PMID: 15654334]

Cohen, J.C.; Boerwinkle, E.; Mosley, T.H., Jr; Hobbs, H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006, 354(12), 1264-1272.
[http://dx.doi.org/10.1056/NEJMoa054013] [PMID: 16554528]

Hooper, A.J.; Marais, A.D.; Tanyanyiwa, D.M.; Burnett, J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis, 2007, 193(2), 445-448.
[http://dx.doi.org/10.1016/j.atherosclerosis.2006.08.039] [PMID: 16989838]

Fasano, T.; Cefalù, A.B.; Di Leo, E.; Noto, D.; Pollaccia, D.; Bocchi, L.; Valenti, V.; Bonardi, R.; Guardamagna, O.; Averna, M.; Tarugi, P. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler. Thromb. Vasc. Biol., 2007, 27(3), 677-681.
[http://dx.doi.org/10.1161/01.ATV.0000255311.26383.2f] [PMID: 17170371]

Zhao, Z.; Tuakli-Wosornu, Y.; Lagace, T.A.; Kinch, L.; Grishin, N.V.; Horton, J.D.; Cohen, J.C.; Hobbs, H.H. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet., 2006, 79(3), 514-523.
[http://dx.doi.org/10.1086/507488] [PMID: 16909389]

Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; Sever, P.S.; Pedersen, T.R. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med., 2017, 376(18), 1713-1722.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]

Leren, T.P. Cascade genetic screening for familial hypercholesterolemia. Clin. Genet., 2004, 66(6), 483-487.
[http://dx.doi.org/10.1111/j.1399-0004.2004.00320.x] [PMID: 15521974]

Shioji, K.; Mannami, T.; Kokubo, Y.; Inamoto, N.; Takagi, S.; Goto, Y.; Nonogi, H.; Iwai, N. Genetic variants in PCSK9 affect the choles-terol level in Japanese. J. Hum. Genet., 2004, 49(2), 109-114.
[http://dx.doi.org/10.1007/s10038-003-0114-3] [PMID: 14727156]

Timms, K.M.; Wagner, S.; Samuels, M.E.; Forbey, K.; Goldfine, H.; Jammulapati, S.; Skolnick, M.H.; Hopkins, P.N.; Hunt, S.C.; Shattuck, D.M. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet., 2004, 114(4), 349-353.
[http://dx.doi.org/10.1007/s00439-003-1071-9] [PMID: 14727179]

Mayer, G.; Poirier, S.; Seidah, N.G. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem., 2008, 283(46), 31791-31801.
[http://dx.doi.org/10.1074/jbc.M805971200] [PMID: 18799458]

Cunningham, D.; Danley, D.E.; Geoghegan, K.F.; Griffor, M.C.; Hawkins, J.L.; Subashi, T.A.; Varghese, A.H.; Ammirati, M.J.; Culp, J.S.; Hoth, L.R.; Mansour, M.N.; McGrath, K.M.; Seddon, A.P.; Shenolikar, S.; Stutzman-Engwall, K.J.; Warren, L.C.; Xia, D.; Qiu, X. Structur-al and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol., 2007, 14(5), 413-419.
[http://dx.doi.org/10.1038/nsmb1235] [PMID: 17435765]

Turpeinen, H.; Ortutay, Z.; Pesu, M. Genetics of the first seven proprotein convertase enzymes in health and disease. Curr. Genomics, 2013, 14(7), 453-467.
[http://dx.doi.org/10.2174/1389202911314050010] [PMID: 24396277]

Hampton, E.N.; Knuth, M.W.; Li, J.; Harris, J.L.; Lesley, S.A.; Spraggon, G. The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain. Proc. Natl. Acad. Sci. USA, 2007, 104(37), 14604-14609.
[http://dx.doi.org/10.1073/pnas.0703402104] [PMID: 17804797]

Piper, D.E.; Jackson, S.; Liu, Q.; Romanow, W.G.; Shetterly, S.; Thibault, S.T.; Shan, B.; Walker, N.P.C. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure, 2007, 15(5), 545-552.
[http://dx.doi.org/10.1016/j.str.2007.04.004] [PMID: 17502100]

McNutt, M.C.; Lagace, T.A.; Horton, J.D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem., 2007, 282(29), 20799-20803.
[http://dx.doi.org/10.1074/jbc.C700095200] [PMID: 17537735]

Li, J.; Tumanut, C.; Gavigan, J.A.; Huang, W.J.; Hampton, E.N.; Tumanut, R.; Suen, K.F.; Trauger, J.W.; Spraggon, G.; Lesley, S.A.; Liau, G.; Yowe, D.; Harris, J.L. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem. J., 2007, 406(2), 203-207.
[http://dx.doi.org/10.1042/BJ20070664] [PMID: 17608623]

Fisher, T.S.; Surdo, P.L.; Pandit, S.; Mattu, M.; Santoro, J.C.; Wisniewski, D.; Cummings, R.T.; Calzetta, A.; Cubbon, R.M.; Fischer, P.A.; Tarachandani, A.; De Francesco, R.; Wright, S.D.; Sparrow, C.P.; Carfi, A.; Sitlani, A. Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation. J. Biol. Chem., 2007, 282(28), 20502-20512.
[http://dx.doi.org/10.1074/jbc.M701634200] [PMID: 17493938]

Pearlstein, R.A.; Hu, Q.Y.; Zhou, J.; Yowe, D.; Levell, J.; Dale, B.; Kaushik, V.K.; Daniels, D.; Hanrahan, S.; Sherman, W.; Abel, R. New hypotheses about the structure-function of proprotein convertase subtilisin/kexin type 9: Analysis of the epidermal growth factorlike repeat A docking site using WaterMap. Proteins, 2010, 78(12), n/a.
[http://dx.doi.org/10.1002/prot.22767] [PMID: 20589640]

Zhang, D.W.; Garuti, R.; Tang, W.J.; Cohen, J.C.; Hobbs, H.H.; Cohen, J.; Fau-Hobbs, H.H.; Hobbs, H.H. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. USA, 2008, 105(35), 13045-13050.
[http://dx.doi.org/10.1073/pnas.0806312105] [PMID: 18753623]

Mousavi, S.A.; Berge, K.E.; Berg, T.; Leren, T.P. Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells. FEBS J., 2011, 278(16), 2938-2950.
[http://dx.doi.org/10.1111/j.1742-4658.2011.08219.x] [PMID: 21692990]

Ai, X.; Fischer, P.; Palyha, O.C.; Wisniewski, D.; Hubbard, B.; Akinsanya, K.; Strack, A.M.; Ehrhardt, A.G. Utilizing HaloTag technology to track the fate of PCSK9 from intracellular vs. extracellular sources. Curr. Chem. Genomics, 2012, 6, 38-47.
[PMID: 23115612]

Cai, G.; Yu, L.; Huang, Z.; Li, L.; Fu, X. Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population. Lipids Health Dis., 2018, 17(1), 213.
[http://dx.doi.org/10.1186/s12944-018-0859-5] [PMID: 30205809]

Maxwell, K.N.; Breslow, J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA, 2004, 101(18), 7100-7105.
[http://dx.doi.org/10.1073/pnas.0402133101] [PMID: 15118091]

Moris, D.; Giaginis, C.; Tsourouflis, G.; Theocharis, S. Farnesoid-X receptor (FXR) as a promising pharmaceutical target in atherosclero-sis. Curr. Med. Chem., 2017, 24(11), 1147-1157.
[PMID: 28120707]

Holla, Ø.L.; Strøm, T.B.; Cameron, J.; Berge, K.E.; Leren, T.P. A chimeric LDL receptor containing the cytoplasmic domain of the transfer-rin receptor is degraded by PCSK9. Mol. Genet. Metab., 2010, 99(2), 149-156.
[http://dx.doi.org/10.1016/j.ymgme.2009.09.012] [PMID: 19828345]

Strøm, T.B.; Holla, Ø.L.; Tveten, K.; Cameron, J.; Berge, K.E.; Leren, T.P. Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain. Mol. Genet. Metab., 2010, 101(1), 76-80.
[http://dx.doi.org/10.1016/j.ymgme.2010.05.003] [PMID: 20659812]

Lakoski, S.G.; Lagace, T.A.; Cohen, J.C.; Horton, J.D.; Hobbs, H.H. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab., 2009, 94(7), 2537-2543.
[http://dx.doi.org/10.1210/jc.2009-0141] [PMID: 19351729]

Steinl, D.; Kaufmann, B. Ultrasound imaging for risk assessment in atherosclerosis. Int. J. Mol. Sci., 2015, 16(12), 9749-9769.
[http://dx.doi.org/10.3390/ijms16059749] [PMID: 25938969]

Stocker, R.; Keaney, J.F., Jr Role of oxidative modifications in atherosclerosis. Physiol. Rev., 2004, 84(4), 1381-1478.
[http://dx.doi.org/10.1152/physrev.00047.2003] [PMID: 15383655]

Kunsch, C.; Medford, R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res., 1999, 85(8), 753-766.
[http://dx.doi.org/10.1161/01.RES.85.8.753] [PMID: 10521248]

Witztum, J.L.; Steinberg, D. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest., 1991, 88(6), 1785-1792.
[http://dx.doi.org/10.1172/JCI115499] [PMID: 1752940]

Marui, N.; Offermann, M.K.; Swerlick, R.; Kunsch, C.; Rosen, C.A.; Ahmad, M.; Alexander, R.W.; Medford, R.M. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular en-dothelial cells. J. Clin. Invest., 1993, 92(4), 1866-1874.
[http://dx.doi.org/10.1172/JCI116778] [PMID: 7691889]

Karampetsou, N.; Tzani, A.; Doulamis, I.P.; Bletsa, E.; Minia, A.; Pliaka, V.; Tsolakos, N.; Oikonomou, E.; Tousoulis, D.; Kontzoglou, K.; Alexopoulos, L.G.; Perrea, D.N.; Patapis, P.; Chloroyiannis, I.A. Epicardial adipocyte-derived TNF-α modulates local inflammation in pa-tients with advanced coronary artery disease. Curr. Vasc. Pharmacol., 2022, 20(1), 87-93.
[http://dx.doi.org/10.2174/1570161119666211029110813] [PMID: 34719373]

Majumdar, S.; Chen, A.; Palmer-Smith, H.; Basak, A. Novel circular, cyclic and acyclic Ψ(CH2O) containing peptide inhibitors of SKI-1/S1P: synthesis, kinetic and biochemical evaluations. Curr. Med. Chem., 2011, 18(18), 2770-2782.
[http://dx.doi.org/10.2174/092986711796011265] [PMID: 21568902]

Lalou, C.; Basak, A.; Mishra, P.; Mohanta, B.C.; Banik, R.; Dinda, B.; Khatib, A.M. Inhibition of tumor cells proliferation and migration by the flavonoid furin inhibitor isolated from Oroxylum indicum. Curr. Med. Chem., 2013, 20(4), 583-591.
[PMID: 23210773]

Bevilacqua, M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol., 1993, 11(1), 767-804.
[http://dx.doi.org/10.1146/annurev.iy.11.040193.004003] [PMID: 8476577]

Huo, Y.; Hafezi-Moghadam, A.; Ley, K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ. Res., 2000, 87(2), 153-159.
[http://dx.doi.org/10.1161/01.RES.87.2.153] [PMID: 10904000]

Patriki, D.; Saravi, S.S.S.; Camici, G.G.; Liberale, L.; Beer, J.H. PCSK 9: A link between inflammation and atherosclerosis. Curr. Med. Chem., 2022, 29(2), 251-267.
[http://dx.doi.org/10.2174/0929867328666210707192625] [PMID: 34238141]

Poredos, P.; Jezovnik, M.K. The role of inflammatory biomarkers in the detection and therapy of atherosclerotic disease. Curr. Vasc. Pharmacol., 2016, 14(6), 534-546.
[http://dx.doi.org/10.2174/1570161114666160625080104] [PMID: 27357185]

Siasos, G.; Tsigkou, V.; Kokkou, E.; Oikonomou, E.; Vavuranakis, M.; Vlachopoulos, C.; Verveniotis, A.; Limperi, M.; Genimata, V.; Papavassiliou, A.; Stefanadis, C.; Tousoulis, D. Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. Curr. Med. Chem., 2014, 21(34), 3936-3948.
[http://dx.doi.org/10.2174/092986732134141015161539] [PMID: 25174928]

Roycik, M.; Myers, J.; Newcomer, R.; Sang, Q.X. Matrix metalloproteinase inhibition in atherosclerosis and stroke. Curr. Mol. Med., 2013, 13(8), 1299-1313.
[http://dx.doi.org/10.2174/15665240113139990067] [PMID: 23865428]

Nagy, B., Jr; Miszti-Blasius, K.; Kerenyi, A.; Clemetson, K.J.; Kappelmayer, J. Potential therapeutic targeting of platelet-mediated cellular interactions in atherosclerosis and inflammation. Curr. Med. Chem., 2012, 19(4), 518-531.
[http://dx.doi.org/10.2174/092986712798918770] [PMID: 22204330]

McMaster pathophysiology review: Atherosclerosis. http://www. pathophys.org/atherosclerosis/#DefinitionOverview(Accessed on: September 15, 2021)

Stroes, E.; Colquhoun, D.; Sullivan, D.; Civeira, F.; Rosenson, R.S.; Watts, G.F.; Bruckert, E.; Cho, L.; Dent, R.; Knusel, B.; Xue, A.; Scott, R.; Wasserman, S.M.; Rocco, M. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 ran-domized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol., 2014, 63(23), 2541-2548.
[http://dx.doi.org/10.1016/j.jacc.2014.03.019] [PMID: 24694531]

Moriarty, P.M.; Thompson, P.D.; Cannon, C.P.; Guyton, J.R.; Bergeron, J.; Zieve, F.J.; Bruckert, E.; Jacobson, T.A.; Kopecky, S.L.; Bacca-ra-Dinet, M.T.; Du, Y.; Pordy, R.; Gipe, D.A. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin re-challenge arm: The ODYSSEY ALTERNATIVE randomized trial. J. Clin. Lipidol., 2015, 9(6), 758-769.
[http://dx.doi.org/10.1016/j.jacl.2015.08.006] [PMID: 26687696]

George, M.; Goenka, L. Alirocumab in post ACS patients - saving lives at a premium Curr. Cardiol. Rev, 2022, 18(1), e030621193814.
[http://dx.doi.org/10.2174/1573403X17666210603111158] [PMID: 34082687]

Cannon, C.P.; Cariou, B.; Blom, D.; McKenney, J.M.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Colhoun, H.M. Efficacy and safety of aliro-cumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J., 2015, 36(19), 1186-1194.
[http://dx.doi.org/10.1093/eurheartj/ehv028] [PMID: 25687353]

Bays, H.; Gaudet, D.; Weiss, R.; Ruiz, J.L.; Watts, G.F.; Gouni-Berthold, I.; Robinson, J.; Zhao, J.; Hanotin, C.; Donahue, S. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY options I Randomized Trial. J. Clin. Endocrinol. Metab., 2015, 100(8), 3140-3148.
[http://dx.doi.org/10.1210/jc.2015-1520] [PMID: 26030325]

Farnier, M.; Jones, P.; Severance, R.; Averna, M.; Steinhagen-Thiessen, E.; Colhoun, H.M.; Du, Y.; Hanotin, C.; Donahue, S. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The odyssey options II randomized trial. Atherosclerosis, 2016, 244, 138-146.
[http://dx.doi.org/10.1016/j.atherosclerosis.2015.11.010] [PMID: 26638010]

Mayne, J.; Dewpura, T.; Raymond, A.; Cousins, M.; Chaplin, A.; Lahey, K.A.; LaHaye, S.A.; Mbikay, M.; Ooi, T.; Chrétien, M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis., 2008, 7(1), 22.
[http://dx.doi.org/10.1186/1476-511X-7-22] [PMID: 18547436]

Food and Drug Administration Center for Drug Evaluation and Research The Endocrinologic and Metabolic Drugs Advisory Committee Meeting.,, 2015. Available from: https://www.fdanews. com/ext/resources/files/06-15/06-15-FDA-AdCom.pdf?15(Accessed on: December 10, 2021)

Food and Drug Administration Center for Drug Evaluation and Research The Endocrinologic and Metabolic Drugs Advisory Committee Meeting., 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM450072.pdf(Accessed on: December 10, 2021)

Swiger, K.J.; Martin, S.S. PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials. Drug Saf., 2015, 38(6), 519-526.
[http://dx.doi.org/10.1007/s40264-015-0296-6] [PMID: 25989944]

EBBINGHAUS Evaluating PCSK9 binding antibody influence on cognitive health in high cardiovascular risk subjects., Available from: https://clinicaltrials.gov/ct2/show/sNCT02207634(Accessed December 12, 2021)

Ott, B.R.; Daiello, L.A.; Dahabreh, I.J.; Springate, B.A.; Bixby, K.; Murali, M.; Trikalinos, T.A. Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials. J. Gen. Intern. Med., 2015, 30(3), 348-358.
[http://dx.doi.org/10.1007/s11606-014-3115-3] [PMID: 25575908]

Robinson, J.G.; Farnier, M.; Krempf, M.; Bergeron, J.; Luc, G.; Averna, M.; Stroes, E.S.; Langslet, G.; Raal, F.J.; El Shahawy, M.; Koren, M.J.; Lepor, N.E.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Kastelein, J.J.P. Efficacy and safety of alirocumab in reducing lipids and cardi-ovascular events. N. Engl. J. Med., 2015, 372(16), 1489-1499.
[http://dx.doi.org/10.1056/NEJMoa1501031] [PMID: 25773378]

Sabatine, M.S.; Giugliano, R.P.; Wiviott, S.D.; Raal, F.J.; Blom, D.J.; Robinson, J.; Ballantyne, C.M.; Somaratne, R.; Legg, J.; Wasserman, S.M.; Scott, R.; Koren, M.J.; Stein, E.A. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med., 2015, 372(16), 1500-1509.
[http://dx.doi.org/10.1056/NEJMoa1500858] [PMID: 25773607]

Auer, J.; Berent, R.; Primus, C. PCSK9 inhibitors and cardiovascular events. N. Engl. J. Med., 2015, 373(8), 773-775.
[http://dx.doi.org/10.1056/NEJMc1508222] [PMID: 26287855]

Charan, K.; Goyal, A.; Gupta, J.K.; Yadav, H.N. Role of atrial natriuretic peptide in ischemic preconditioning–induced cardioprotection in the diabetic rat heart. J. Surg. Res., 2016, 201(2), 272-278.
[http://dx.doi.org/10.1016/j.jss.2015.10.045] [PMID: 27020807]

Chapman, M.J.; Stock, J.K.; Ginsberg, H.N. PCSK9 inhibitors and cardiovascular disease. Curr. Opin. Lipidol., 2015, 26(6), 511-520.
[http://dx.doi.org/10.1097/MOL.0000000000000239] [PMID: 26780005]

Felekos, I.; Karamasis, G.V.; Pavlidis, A.N. PCSK9 inhibitors for the management of dyslipidemia in people with type 2 diabetes: How low is too low? Curr. Pharm. Des., 2021, 27(8), 1008-1014.
[http://dx.doi.org/10.2174/1381612826666200617170252] [PMID: 32552640]

Anthoulakis, C.; Mamopoulos, A.; Rousso, D.; Karagiannis, A.; Athanasiadis, A.; Grimbizis, G.; Athyros, V. Arterial stiffness as a cardio-vascular risk factor for the development of preeclampsia and pharmacopreventive options. Curr. Vasc. Pharmacol., 2022, 20(1), 52-61.
[http://dx.doi.org/10.2174/1570161119666211006114258] [PMID: 34615450]

Espinoza, C.; Fuenzalida, B.; Leiva, A. Increased fetal cardiovascular disease risk: Potential synergy between gestational diabetes mellitus and maternal hypercholesterolemia. Curr. Vasc. Pharmacol., 2021, 19(6), 601-623.
[http://dx.doi.org/10.2174/1570161119666210423085407] [PMID: 33902412]

Raal, F.J.; Stein, E.A.; Dufour, R.; Turner, T.; Civeira, F.; Burgess, L.; Langslet, G.; Scott, R.; Olsson, A.G.; Sullivan, D.; Hovingh, G.K.; Cariou, B.; Gouni-Berthold, I.; Somaratne, R.; Bridges, I.; Scott, R.; Wasserman, S.M.; Gaudet, D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet, 2015, 385(9965), 331-340.
[http://dx.doi.org/10.1016/S0140-6736(14)61399-4] [PMID: 25282519]

Kastelein, J.J.P.; Ginsberg, H.N.; Langslet, G.; Hovingh, G.K.; Ceska, R.; Dufour, R.; Blom, D.; Civeira, F.; Krempf, M.; Lorenzato, C.; Zhao, J.; Pordy, R.; Baccara-Dinet, M.T.; Gipe, D.A.; Geiger, M.J.; Farnier, M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J., 2015, 36(43)ehv370
[http://dx.doi.org/10.1093/eurheartj/ehv370] [PMID: 26330422]

Ginsberg, H.N.; Rader, D.J.; Raal, F.J.; Guyton, J.; Lorenzato, C.; Pordy, R.; Baccara-Dinet, M.T.; Stroes, E. ODYSSEY high FH: Efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia. Circulation, 2014, 130(23), 2119.

Agrawal, V.; Gupta, J.K.; Qureshi, S.S.; Vishwakarma, V.K. Role of cardiac renin angiotensin system in ischemia reperfusion injury and preconditioning of heart. Indian Heart J., 2016, 68(6), 856-861.
[http://dx.doi.org/10.1016/j.ihj.2016.06.010] [PMID: 27931559]

Seidah, N.G.; Benjannet, S.; Wickham, L.; Marcinkiewicz, J.; Jasmin, S.B.; Stifani, S.; Basak, A.; Prat, A.; Chrétien, M. The secretory pro-protein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA, 2003, 100(3), 928-933.
[http://dx.doi.org/10.1073/pnas.0335507100] [PMID: 12552133]

Costet, P.; Cariou, B.; Lambert, G.; Lalanne, F.; Lardeux, B.; Jarnoux, A.L.; Grefhorst, A.; Staels, B.; Krempf, M. Hepatic PCSK9 expres-sion is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J. Biol. Chem., 2006, 281(10), 6211-6218.
[http://dx.doi.org/10.1074/jbc.M508582200] [PMID: 16407292]

Jeong, H.J.; Lee, H.S.; Kim, K.S.; Kim, Y.K.; Yoon, D.; Park, S.W. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J. Lipid Res., 2008, 49(2), 399-409.
[http://dx.doi.org/10.1194/jlr.M700443-JLR200] [PMID: 17921436]

Rong, S.; Cortés, V.A.; Rashid, S.; Anderson, N.N.; McDonald, J.G.; Liang, G.; Moon, Y.A.; Hammer, R.E.; Horton, J.D. Expression of SREBP-1c requires SREBP-2-mediated generation of a sterol ligand for LXR in livers of mice eLife, 2017, 6e25015.
[http://dx.doi.org/10.7554/eLife.25015] [PMID: 28244871]

Li, H.; Dong, B.; Park, S.W.; Lee, H.S.; Chen, W.; Liu, J. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J. Biol. Chem., 2009, 284(42), 28885-28895.
[http://dx.doi.org/10.1074/jbc.M109.052407] [PMID: 19687008]

Dong, B.; Wu, M.; Li, H.; Kraemer, F.B.; Adeli, K.; Seidah, N.G.; Park, S.W.; Liu, J. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res., 2010, 51(6), 1486-1495.
[http://dx.doi.org/10.1194/jlr.M003566] [PMID: 20048381]

Shende, V.R.; Wu, M.; Singh, A.B.; Dong, B.; Kan, C.F.K.; Liu, J. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice. J. Lipid Res., 2015, 56(4), 801-809.
[http://dx.doi.org/10.1194/jlr.M052969] [PMID: 25652089]

Puri, R.; Mehta, V.; Duell, P.B.; Nair, D.; Mohan, J.C.; Yusuf, J.; Dalal, J.J.; Mishra, S.; Kasliwal, R.R.; Agarwal, R.; Mukhopadhyay, S.; Wardhan, H.; Khanna, N.N.; Pradhan, A.; Mehrotra, R.; Kumar, A.; Puri, S.; Muruganathan, A.; Sattur, G.B.; Yadav, M.; Singh, H.P.; Agarwal, R.K.; Nanda, R. Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. J. Clin. Lipidol., 2020, 14(2), e1-e13.
[http://dx.doi.org/10.1016/j.jacl.2020.01.006] [PMID: 32089456]

Rosenson, R.S.; Hegele, R.A.; Fazio, S.; Cannon, C.P. The evolving future of PCSK9 inhibitors. J. Am. Coll. Cardiol., 2018, 72(3), 314-329.
[http://dx.doi.org/10.1016/j.jacc.2018.04.054] [PMID: 30012326]

Dubuc, G.; Chamberland, A.; Wassef, H.; Davignon, J.; Seidah, N.G.; Bernier, L.; Prat, A. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol., 2004, 24(8), 1454-1459.
[http://dx.doi.org/10.1161/01.ATV.0000134621.14315.43] [PMID: 15178557]

Rashid, S.; Curtis, D.E.; Garuti, R.; Anderson, N.N.; Bashmakov, Y.; Ho, Y.K.; Hammer, R.E.; Moon, Y.A.; Horton, J.D. Decreased plas-ma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA, 2005, 102(15), 5374-5379.
[http://dx.doi.org/10.1073/pnas.0501652102] [PMID: 15805190]

Careskey, H.E.; Davis, R.A.; Alborn, W.E.; Troutt, J.S.; Cao, G.; Konrad, R.J. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res., 2008, 49(2), 394-398.
[http://dx.doi.org/10.1194/jlr.M700437-JLR200] [PMID: 18033751]

Sahebkar, A. Circulating levels of proprotein convertase subtilisin kexin type 9 are elevated by fibrate therapy: a systematic review and meta-analysis of clinical trials. Cardiol. Rev., 2014, 22(6), 306-312.
[http://dx.doi.org/10.1097/CRD.0000000000000025] [PMID: 24614537]

Troutt, J.S.; Alborn, W.E.; Cao, G.; Konrad, R.J. Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J. Lipid Res., 2010, 51(2), 345-351.
[http://dx.doi.org/10.1194/jlr.M000620] [PMID: 19738285]

Ma, D.; Liu, T.; Chang, L.; Rui, C.; Xiao, Y.; Li, S.; Hogenesch, J.B.; Chen, Y.E.; Lin, J.D. The liver clock controls cholesterol homeostasis through Trib1 protein-mediated regulation of PCSK9/low density lipoprotein receptor (LDL-R) axis. J. Biol. Chem., 2015, 290(52), 31003-31012.
[http://dx.doi.org/10.1074/jbc.M115.685982] [PMID: 26547624]

Ochin, C.C.; Garelnabi, M. Berberine encapsulated PLGA-PEG nanoparticles modulate PCSK-9 in HepG2 Cells. Cardiovasc. Hematol. Disord. Drug Targets, 2018, 18(1), 61-70.
[http://dx.doi.org/10.2174/1871529X18666180201130340] [PMID: 29422010]

Wang, X.; Chen, X.; Zhang, X.; Su, C.; Yang, M.; He, W.; Du, Y.; Si, S.; Wang, L.; Hong, B. A small-molecule inhibitor of PCSK9 transcription ameliorates atherosclerosis through the modulation ofFoxO1/3 and HNF1α EBioMedicine, 2020, 52, 102650.
[http://dx.doi.org/10.1016/j.ebiom.2020.102650] [PMID: 32058941]

Lin, X.L.; Xiao, L.L.; Tang, Z.H.; Jiang, Z.S.; Liu, M.H. Role of PCSK9 in lipid metabolism and atherosclerosis. Biomed. Pharmacother., 2018, 104, 36-44.
[http://dx.doi.org/10.1016/j.biopha.2018.05.024] [PMID: 29758414]

Basak, S.; Lu, C.; Basak, A. Post-translational protein modifications of rare and unconventional types: Implications in functions and dis-eases. Curr. Med. Chem., 2016, 23(7), 714-745.
[http://dx.doi.org/10.2174/0929867323666160118095620] [PMID: 26778322]

Tavridou, A.; Manolopoulos, V. Novel molecules targeting dyslipidemia and atherosclerosis. Curr. Med. Chem., 2008, 15(8), 792-802.
[http://dx.doi.org/10.2174/092986708783955482] [PMID: 18393849]

Urban, D.; Pöss, J.; Böhm, M.; Laufs, U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol., 2013, 62(16), 1401-1408.
[http://dx.doi.org/10.1016/j.jacc.2013.07.056] [PMID: 23973703]

Elbitar, S.; Khoury, P.E.; Ghaleb, Y.; Rabès, J.P.; Varret, M.; Seidah, N.G.; Boileau, C.; Abifadel, M. Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). Expert Opin. Ther. Pat., 2016, 26(12), 1377-1392.
[http://dx.doi.org/10.1080/13543776.2016.1206080] [PMID: 27359211]

Catapano, A.L.; Pirillo, A.; Norata, G.D. New pharmacological approaches to target PCSK9. Curr. Atheroscler. Rep., 2020, 22(7), 24.
[http://dx.doi.org/10.1007/s11883-020-00847-7] [PMID: 32495301]

Nishikido, T.; Ray, K.K. Non-antibody approaches to proprotein convertase subtilisin kexin 9 inhibition: siRNA, antisense oligonucleo-tides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries. Front. Cardiovasc. Med., 2019, 5, 199.
[http://dx.doi.org/10.3389/fcvm.2018.00199] [PMID: 30761308]

Katzmann, J.L.; Packard, C.J.; Chapman, M.J.; Katzmann, I.; Laufs, U. Targeting RNA with antisense oligonucleotides and small interfering RNA in dyslipidemias. J. Am. Coll. Cardiol., 2020, 76(5), 563-579.
[http://dx.doi.org/10.1016/j.jacc.2020.05.070] [PMID: 32731935]

Ference, B.A.; Yoo, W.; Alesh, I.; Mahajan, N.; Mirowska, K.K.; Mewada, A.; Kahn, J.; Afonso, L.; Williams, K.A., Sr; Flack, J.M. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendeli-an randomization analysis. J. Am. Coll. Cardiol., 2012, 60(25), 2631-2639.
[http://dx.doi.org/10.1016/j.jacc.2012.09.017] [PMID: 23083789]

Ference, B.A.; Robinson, J.G.; Brook, R.D.; Catapano, A.L.; Chapman, M.J.; Neff, D.R.; Voros, S.; Giugliano, R.P.; Davey Smith, G.; Fazio, S.; Sabatine, M.S. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N. Engl. J. Med., 2016, 375(22), 2144-2153.
[http://dx.doi.org/10.1056/NEJMoa1604304] [PMID: 27959767]

Schunkert, H.; König, I.R.; Kathiresan, S.; Reilly, M.P.; Assimes, T.L.; Holm, H.; Preuss, M.; Stewart, A.F.R.; Barbalic, M.; Gieger, C.; Absher, D.; Aherrahrou, Z.; Allayee, H.; Altshuler, D.; Anand, S.S.; Andersen, K.; Anderson, J.L.; Ardissino, D.; Ball, S.G.; Balmforth, A.J.; Barnes, T.A.; Becker, D.M.; Becker, L.C.; Berger, K.; Bis, J.C.; Boekholdt, S.M.; Boerwinkle, E.; Braund, P.S.; Brown, M.J.; Burnett, M.S.; Buysschaert, I.; Carlquist, J.F.; Chen, L.; Cichon, S.; Codd, V.; Davies, R.W.; Dedoussis, G.; Dehghan, A.; Demissie, S.; Devaney, J.M.; Diemert, P.; Do, R.; Doering, A.; Eifert, S.; Mokhtari, N.E.E.; Ellis, S.G.; Elosua, R.; Engert, J.C.; Epstein, S.E.; de Faire, U.; Fischer, M.; Folsom, A.R.; Freyer, J.; Gigante, B.; Girelli, D.; Gretarsdottir, S.; Gudnason, V.; Gulcher, J.R.; Halperin, E.; Hammond, N.; Hazen, S.L.; Hofman, A.; Horne, B.D.; Illig, T.; Iribarren, C.; Jones, G.T.; Jukema, J.W.; Kaiser, M.A.; Kaplan, L.M.; Kastelein, J.J.P.; Khaw, K.T.; Knowles, J.W.; Kolovou, G.; Kong, A.; Laaksonen, R.; Lambrechts, D.; Leander, K.; Lettre, G.; Li, M.; Lieb, W.; Loley, C.; Lotery, A.J.; Mannucci, P.M.; Maouche, S.; Martinelli, N.; McKeown, P.P.; Meisinger, C.; Meitinger, T.; Melander, O.; Merlini, P.A.; Mooser, V.; Mor-gan, T.; Mühleisen, T.W.; Muhlestein, J.B.; Münzel, T.; Musunuru, K.; Nahrstaedt, J.; Nelson, C.P.; Nöthen, M.M.; Olivieri, O.; Patel, R.S.; Patterson, C.C.; Peters, A.; Peyvandi, F.; Qu, L.; Quyyumi, A.A.; Rader, D.J.; Rallidis, L.S.; Rice, C.; Rosendaal, F.R.; Rubin, D.; Salomaa, V.; Sampietro, M.L.; Sandhu, M.S.; Schadt, E.; Schäfer, A.; Schillert, A.; Schreiber, S.; Schrezenmeir, J.; Schwartz, S.M.; Siscovick, D.S.; Sivananthan, M.; Sivapalaratnam, S.; Smith, A.; Smith, T.B.; Snoep, J.D.; Soranzo, N.; Spertus, J.A.; Stark, K.; Stirrups, K.; Stoll, M.; Tang, W.H.W.; Tennstedt, S.; Thorgeirsson, G.; Thorleifsson, G.; Tomaszewski, M.; Uitterlinden, A.G.; van Rij, A.M.; Voight, B.F.; Wareham, N.J.; Wells, G.A.; Wichmann, H.E.; Wild, P.S.; Willenborg, C.; Witteman, J.C.M.; Wright, B.J.; Ye, S.; Zeller, T.; Ziegler, A.; Cambien, F.; Goodall, A.H.; Cupples, L.A.; Quertermous, T.; März, W.; Hengstenberg, C.; Blankenberg, S.; Ouwehand, W.H.; Hall, A.S.; Deloukas, P.; Thompson, J.R.; Stefansson, K.; Roberts, R.; Thorsteinsdottir, U.; O’Donnell, C.J.; McPherson, R.; Erdmann, J.; Samani, N.J.; Samani, N.J. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet., 2011, 43(4), 333-338.
[http://dx.doi.org/10.1038/ng.784] [PMID: 21378990]

Deloukas, P.; Kanoni, S.; Willenborg, C.; Farrall, M.; Assimes, T.L.; Thompson, J.R.; Ingelsson, E.; Saleheen, D.; Erdmann, J.; Goldstein, B.A.; Stirrups, K.; König, I.R.; Cazier, J.B.; Johansson, Å.; Hall, A.S.; Lee, J.Y.; Willer, C.J.; Chambers, J.C.; Esko, T.; Folkersen, L.; Goel, A.; Grundberg, E.; Havulinna, A.S.; Ho, W.K.; Hopewell, J.C.; Eriksson, N.; Kleber, M.E.; Kristiansson, K.; Lundmark, P.; Lyytikäinen, L.P.; Rafelt, S.; Shungin, D.; Strawbridge, R.J.; Thorleifsson, G.; Tikkanen, E.; Van Zuydam, N.; Voight, B.F.; Waite, L.L.; Zhang, W.; Ziegler, A.; Absher, D.; Altshuler, D.; Balmforth, A.J.; Barroso, I.; Braund, P.S.; Burgdorf, C.; Claudi-Boehm, S.; Cox, D.; Dimitriou, M.; Do, R.; Doney, A.S.F.; Mokhtari, N.E.E.; Eriksson, P.; Fischer, K.; Fontanillas, P.; Franco-Cereceda, A.; Gigante, B.; Groop, L.; Gus-tafsson, S.; Hager, J.; Hallmans, G.; Han, B.G.; Hunt, S.E.; Kang, H.M.; Illig, T.; Kessler, T.; Knowles, J.W.; Kolovou, G.; Kuusisto, J.; Langenberg, C.; Langford, C.; Leander, K.; Lokki, M.L.; Lundmark, A.; McCarthy, M.I.; Meisinger, C.; Melander, O.; Mihailov, E.; Maouche, S.; Morris, A.D.; Müller-Nurasyid, M.; Nikus, K.; Peden, J.F.; Rayner, N.W.; Rasheed, A.; Rosinger, S.; Rubin, D.; Rumpf, M.P.; Schäfer, A.; Sivananthan, M.; Song, C.; Stewart, A.F.R.; Tan, S.T.; Thorgeirsson, G.; Schoot, C.E.; Wagner, P.J.; Wells, G.A.; Wild, P.S.; Yang, T.P.; Amouyel, P.; Arveiler, D.; Basart, H.; Boehnke, M.; Boerwinkle, E.; Brambilla, P.; Cambien, F.; Cupples, A.L.; de Faire, U.; Dehghan, A.; Diemert, P.; Epstein, S.E.; Evans, A.; Ferrario, M.M.; Ferrières, J.; Gauguier, D.; Go, A.S.; Goodall, A.H.; Gudnason, V.; Ha-zen, S.L.; Holm, H.; Iribarren, C.; Jang, Y.; Kähönen, M.; Kee, F.; Kim, H.S.; Klopp, N.; Koenig, W.; Kratzer, W.; Kuulasmaa, K.; Laakso, M.; Laaksonen, R.; Lee, J.Y.; Lind, L.; Ouwehand, W.H.; Parish, S.; Park, J.E.; Pedersen, N.L.; Peters, A.; Quertermous, T.; Rader, D.J.; Salomaa, V.; Schadt, E.; Shah, S.H.; Sinisalo, J.; Stark, K.; Stefansson, K.; Trégouët, D.A.; Virtamo, J.; Wallentin, L.; Wareham, N.; Zim-mermann, M.E.; Nieminen, M.S.; Hengstenberg, C.; Sandhu, M.S.; Pastinen, T.; Syvänen, A.C.; Hovingh, G.K.; Dedoussis, G.; Franks, P.W.; Lehtimäki, T.; Metspalu, A.; Zalloua, P.A.; Siegbahn, A.; Schreiber, S.; Ripatti, S.; Blankenberg, S.S.; Perola, M.; Clarke, R.; Boehm, B.O.; O’Donnell, C.; Reilly, M.P.; März, W.; Collins, R.; Kathiresan, S.; Hamsten, A.; Kooner, J.S.; Thorsteinsdottir, U.; Danesh, J.; Palmer, C.N.A.; Roberts, R.; Watkins, H.; Schunkert, H.; Samani, N.J. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat. Genet., 2013, 45(1), 25-33.
[http://dx.doi.org/10.1038/ng.2480] [PMID: 23202125]

Chen, B.; Shi, X.; Cui, Y.; Hou, A.; Zhao, P. A review of PCSK9 inhibitors and their effects on cardiovascular diseases. Curr. Top. Med. Chem., 2019, 19(20), 1790-1817.
[http://dx.doi.org/10.2174/1568026619666190809094203] [PMID: 31400268]

Abifadel, M.; Elbitar, S.; El Khoury, P.; Ghaleb, Y.; Chémaly, M.; Moussalli, M.L.; Rabès, J.P.; Varret, M.; Boileau, C. Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr. Atheroscler. Rep., 2014, 16(9), 439.
[http://dx.doi.org/10.1007/s11883-014-0439-8] [PMID: 25052769]

Luna Saavedra, Y.G.; Dufour, R.; Davignon, J.; Baass, A. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercho-lesterolemia: a cross-sectional cohort study. Arterioscler. Thromb. Vasc. Biol., 2014, 34(12), 2700-2705.
[http://dx.doi.org/10.1161/ATVBAHA.114.304406] [PMID: 25278291]

Seidah, N.G.; Awan, Z.; Chrétien, M.; Mbikay, M. PCSK9: a key modulator of cardiovascular health. Circ. Res., 2014, 114(6), 1022-1036.
[http://dx.doi.org/10.1161/CIRCRESAHA.114.301621] [PMID: 24625727]

Ginsberg, H.N.; Rader, D.J.; Raal, F.J.; Guyton, J.R.; Baccara-Dinet, M.T.; Lorenzato, C.; Pordy, R.; Stroes, E. Efficacy and safety of aliro-cumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther., 2016, 30(5), 473-483.
[http://dx.doi.org/10.1007/s10557-016-6685-y] [PMID: 27618825]

Wiegman, A.; Gidding, S.S.; Watts, G.F.; Chapman, M.J.; Ginsberg, H.N.; Cuchel, M.; Ose, L.; Averna, M.; Boileau, C.; Borén, J.; Bruckert, E.; Catapano, A.L.; Defesche, J.C.; Descamps, O.S.; Hegele, R.A.; Hovingh, G.K.; Humphries, S.E.; Kovanen, P.T.; Kuivenhoven, J.A.; Masana, L.; Nordestgaard, B.G.; Pajukanta, P.; Parhofer, K.G.; Raal, F.J.; Ray, K.K.; Santos, R.D.; Stalenhoef, A.F.H. Steinhagen- Thies-sen, E.; Stroes, E.S.; Taskinen, M.R.; Tybjærg-Hansen, A.; Wiklund, O. Familial hypercholesterolaemia in children and adolescents: gain-ing decades of life by optimizing detection and treatment. Eur. Heart J., 2015, 36(36), 2425-2437.
[http://dx.doi.org/10.1093/eurheartj/ehv157] [PMID: 26009596]

Clinical Trials Identifier NCT02392559. Trial assessing efficacy,safety and tolerability of PCSK9 inhibition in paediatric subjects with genetic LDL disorders (HAUSER-RCT). Available from: https://clinicaltrials.gov/ct 2/show/NCT02392559Accessed on January 5, 2022)

Stefanutti, C.; Zenti, M.G. Lipoprotein apheresis and PCSK9-inhibitors. Impact on atherogenic lipoproteins and anti-inflammatory media-tors in familial hypercholesterolaemia. Curr. Pharm. Des., 2019, 24(31), 3634-3637.
[http://dx.doi.org/10.2174/1381612824666181025115658] [PMID: 30360706]

Obradovic, M.; Zaric, B.; Sudar-Milovanovic, E.; Ilincic, B.; Stokic, E.; Perovic, M.; Isenovic, E.R. PCSK9 and hypercholesterolemia: Therapeutic approach. Curr. Drug Targets, 2018, 19(9), 1058-1067.
[http://dx.doi.org/10.2174/1389450119666171205101401] [PMID: 29210646]

Jain, K.S.; Kulkarni, R.R.; Jain, D.P. Current drug targets for antihyperlipidemic therapy. Mini Rev. Med. Chem., 2010, 10(3), 232-262.
[http://dx.doi.org/10.2174/138955710791185037] [PMID: 20105132]

Al-Ashwal, A.; Alnouri, F.; Sabbour, H.; Al-Mahfouz, A.; Al-Sayed, N.; Razzaghy-Azar, M.; Al-Allaf, F.; Al-Waili, K.; Banerjee, Y.; Gen-est, J.; Santos, R.; Al-Rasadi, K. Identification and treatment of patients with homozygous familial hypercholesterolaemia: Information and recommendations from a middle east advisory panel. Curr. Vasc. Pharmacol., 2015, 13(6), 759-770.
[http://dx.doi.org/10.2174/1570161113666150827125040] [PMID: 26311574]

Wu, Q.; Tang, Z.H.; Peng, J.; Liao, L.; Pan, L.H.; Wu, C.Y.; Jiang, Z.S.; Wang, G.X.; Liu, L.S. The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer’s disease progression. Biomed. Rep., 2014, 2(2), 167-171.
[http://dx.doi.org/10.3892/br.2013.213] [PMID: 24649090]

Geary, R.S.; Watanabe, T.A.; Truong, L.; Freier, S.; Lesnik, E.A.; Sioufi, N.B.; Sasmor, H.; Manoharan, M.; Levin, A.A. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J. Pharmacol. Exp. Ther., 2001, 296(3), 890-897.
[PMID: 11181921]

Lagace, T.A.; Curtis, D.E.; Garuti, R.; McNutt, M.C.; Park, S.W.; Prather, H.B.; Anderson, N.N.; Ho, Y.K.; Hammer, R.E.; Horton, J.D. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice. J. Clin. Invest., 2006, 116(11), 2995-3005.
[http://dx.doi.org/10.1172/JCI29383] [PMID: 17080197]

Corjon, S.; Wortmann, A.; Engler, T.; van Rooijen, N.; Kochanek, S.; Kreppel, F. Targeting of adenovirus vectors to the LRP receptor fami-ly with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. Mol. Ther., 2008, 16(11), 1813-1824.
[http://dx.doi.org/10.1038/mt.2008.174] [PMID: 18714309]

Sander, J.D.; Joung, J.K. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol., 2014, 32(4), 347-355.
[http://dx.doi.org/10.1038/nbt.2842] [PMID: 24584096]

Hamilton, A.J.; Baulcombe, D.C. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science, 1999, 286(5441), 950-952.
[http://dx.doi.org/10.1126/science.286.5441.950] [PMID: 10542148]

Wetterau, J.R.; Gregg, R.E.; Harrity, T.W.; Arbeeny, C.; Cap, M.; Connolly, F.; Chu, C.H.; George, R.J.; Gordon, D.A.; Jamil, H.; Jolibois, K.G.; Kunselman, L.K.; Lan, S.J.; Maccagnan, T.J.; Ricci, B.; Yan, M.; Young, D.; Chen, Y.; Fryszman, O.M.; Logan, J.V.H.; Musial, C.L.; Poss, M.A.; Robl, J.A.; Simpkins, L.M.; Slusarchyk, W.A.; Sulsky, R.; Taunk, P.; Magnin, D.R.; Tino, J.A.; Lawrence, R.M.; Dickson, J.K., Jr; Biller, S.A. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science, 1998, 282(5389), 751-754.
[http://dx.doi.org/10.1126/science.282.5389.751] [PMID: 9784135]

Cuchel, M.; Bloedon, L.T.; Szapary, P.O.; Kolansky, D.M.; Wolfe, M.L.; Sarkis, A.; Millar, J.S.; Ikewaki, K.; Siegelman, E.S.; Gregg, R.E.; Rader, D.J. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N. Engl. J. Med., 2007, 356(2), 148-156.
[http://dx.doi.org/10.1056/NEJMoa061189] [PMID: 17215532]

Cuchel, M.; Meagher, E.; Marais, A.D.; Blom, D.J.; Theron, H.D.; Baer, A.L.; Bloedon, L.T.; Sasiela, W.J.; Rader, D.J. A phase III study of microsomal triglyceride transfer protein inhibitor lomitapide (AEGR-733) in patients with homozygous familial hypercholesterolemia: In-terim results at 6 months. Circulation, 2009, 120(18), S441.

Samaha, F.F.; McKenney, J.; Bloedon, L.T.; Sasiela, W.J.; Rader, D.J. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat. Clin. Pract. Cardiovasc. Med., 2008, 5(8), 497-505.
[http://dx.doi.org/10.1038/ncpcardio1250] [PMID: 18506154]

Karpf, D.; Roberts, B.; Martin, R.; Naim, S.; Shukla, U.; Choi, Y.; Krauss, R.; Francis, B.; Farrell, K.; Helmer, E.; Wang, X. MBX- 8025, a potential novel treatment for dyslipidemia and metabolic syndrome: Results of a phase 2 proof-of-concept trial as monotherapy and in combination with atorvastatin. World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). 2008. Available from: http://www.codhy.com/2008/document.aspx?did=2113 (Accessed March 5, 2022).

Ito, B.R.; Zhang, B-H.; Cable, E.E.; Song, X.; Fujitaki, J.M.; MacKenna, D.A.; Wilker, C.E.; Chi, B.; van Poelje, P.D.; Linemeyer, D.L.; Erion, M.D. Thyroid hormone β receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys. Br. J. Pharmacol., 2009, 156(3), 454-465.
[http://dx.doi.org/10.1111/j.1750-3639.2009.00038.x] [PMID: 19183199]

Merki, E.; Graham, M.J.; Mullick, A.E.; Miller, E.R.; Crooke, R.M.; Pitas, R.E.; Witztum, J.L.; Tsimikas, S. Antisense oligonucleotide di-rected to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation, 2008, 118(7), 743-753.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.786822] [PMID: 18663084]

Kastelein, J.J.P.; Wedel, M.K.; Baker, B.F.; Su, J.; Bradley, J.D.; Yu, R.Z.; Chuang, E.; Graham, M.J.; Crooke, R.M. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation, 2006, 114(16), 1729-1735.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.606442] [PMID: 17030687]

Raal, F.J.; Santos, R.D.; Blom, D.J.; Marais, A.D.; Charng, M.J.; Cromwell, W.C.; Lachmann, R.H.; Gaudet, D.; Tan, J.L.; Chasan-Taber, S.; Tribble, D.L.; Flaim, J.D.; Crooke, S.T. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentra-tions in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010, 375(9719), 998-1006.
[http://dx.doi.org/10.1016/S0140-6736(10)60284-X] [PMID: 20227758]

Graham, M.J.; Lemonidis, K.M.; Whipple, C.P.; Subramaniam, A.; Monia, B.P.; Crooke, S.T.; Crooke, R.M. Antisense inhibition of pro-protein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res., 2007, 48(4), 763-767.
[http://dx.doi.org/10.1194/jlr.C600025-JLR200] [PMID: 17242417]

Berkenstam, A.; Kristensen, J.; Mellström, K.; Carlsson, B.; Malm, J.; Rehnmark, S.; Garg, N.; Andersson, C.M.; Rudling, M.; Sjöberg, F.; Angelin, B.; Baxter, J.D. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid syn-thesis without cardiac effects in humans. Proc. Natl. Acad. Sci. USA, 2008, 105(2), 663-667.
[http://dx.doi.org/10.1073/pnas.0705286104] [PMID: 18160532]

Trost, S.U.; Swanson, E.; Gloss, B.; Wang-Iverson, D.B.; Zhang, H.; Volodarsky, T.; Grover, G.J.; Baxter, J.D.; Chiellini, G.; Scanlan, T.S.; Dillmann, W.H. The thyroid hormone receptor-beta-selective agonist GC-1 differentially affects plasma lipids and cardiac activity. Endocrinology, 2000, 141(9), 3057-3064.
[http://dx.doi.org/10.1210/endo.141.9.7681] [PMID: 10965874]

Grover, G.J.; Egan, D.M.; Sleph, P.G.; Beehler, B.C.; Chiellini, G.; Nguyen, N.H.; Baxter, J.D.; Scanlan, T.S. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3′-triiodo-L-thyronine. Endocrinology, 2004, 145(4), 1656-1661.
[http://dx.doi.org/10.1210/en.2003-0973] [PMID: 14701670]

Scanlan, T.S. Sobetirome: a case history of bench-to-clinic drug discovery and development. Heart Fail. Rev., 2010, 15(2), 177-182.
[http://dx.doi.org/10.1007/s10741-008-9122-x] [PMID: 19002578]

Ellis, J.L.; Bartolozzi, A.; Ferkany, J.; Foudoulakis, H.; Kim, E.; Kuo, J.; Ruffing, R.; Schueller, O.; Wong, E.; Yang, Y.; Sweetnam, P. SLx-4090, an enterocyte-specific microsomal triglyceride transport protein inhibitor, lowers LDL cholesterol and triglycerides while raising HDL cholesterol in Apo E -/- mice fed a high-fat diet. Arterioscler. Thromb. Vasc. Biol., 2007, 27, E64-E64.

Prince, W.T.; Tong, W.; Andersen, G.; Campbell, S.; Ferkany, J.; Sweetnam, P.; Koester, F. SLx-4090: First human experience and proof of concept for an enterocyte-specific microsomal triglyceride transfer protein inhibitor. Circulation, 2006, 114, 2427-2427.

Nissen, S.E.; Nicholls, S.J.; Wolski, K.; Howey, D.C.; McErlean, E.; Wang, M.D.; Gomez, E.V.; Russo, J.M. Effects of a potent and selec-tive PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA, 2007, 297(12), 1362-1373.
[http://dx.doi.org/10.1001/jama.297.12.1362] [PMID: 17384435]

Millar, J.S.; Duffy, D.; Gadi, R.; Bloedon, L.T.; Dunbar, R.L.; Wolfe, M.L.; Movva, R.; Shah, A.; Fuki, I.V.; McCoy, M.; Harris, C.J.; Wang, M.D.; Howey, D.C.; Rader, D.J. Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and ca-tabolism in human subjects with the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol., 2009, 29(1), 140-146.
[http://dx.doi.org/10.1161/ATVBAHA.108.171223] [PMID: 18988892]

Gupta, J.; Gupta, R.; Varun, K.; Wahi, N. Application of medicinal plants in management of endogenous bioactive molecules as potential biomarkers for cardiovascular disease and disorders. Curr. Trends Biotechnol. Pharm., 2019, 13(3), 350-365.

Xu, X.; Chai, M.; Cheng, Y.; Peng, P.; Liu, X.; Yan, Z.; Guo, Y.; Zhao, Y.; Zhou, Y. Efficacy and safety of evolocumab in reducing low-density lipoprotein cholesterol levels in chinese patients with non-ST-segment elevation acute coronary syndrome. Curr. Vasc. Pharmacol., 2021, 19(4), 429-437.
[http://dx.doi.org/10.2174/1570161118666200616144141] [PMID: 32543364]

Liang, H.; Chaparro-Riggers, J.; Strop, P.; Geng, T.; Sutton, J.E.; Tsai, D.; Bai, L.; Abdiche, Y.; Dilley, J.; Yu, J.; Wu, S.; Chin, S.M.; Lee, N.A.; Rossi, A.; Lin, J.C.; Rajpal, A.; Pons, J.; Shelton, D.L. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J. Pharmacol. Exp. Ther., 2012, 340(2), 228-236.
[http://dx.doi.org/10.1124/jpet.111.187419] [PMID: 22019884]

Kereiakes, D.J.; Robinson, J.G.; Cannon, C.P.; Lorenzato, C.; Pordy, R.; Chaudhari, U.; Colhoun, H.M. Efficacy and safety of the propro-tein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study. Am. Heart J., 2015, 169(6), 906-915.e13.
[http://dx.doi.org/10.1016/j.ahj.2015.03.004] [PMID: 26027630]

Koren, M.J.; Giugliano, R.P.; Raal, F.J.; Sullivan, D.; Bolognese, M.; Langslet, G.; Civeira, F.; Somaratne, R.; Nelson, P.; Liu, T.; Scott, R.; Wasserman, S.M.; Sabatine, M.S. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercho-lesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation, 2014, 129(2), 234-243.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.007012] [PMID: 24255061]

Blom, D.J.; Hala, T.; Bolognese, M.; Lillestol, M.J.; Toth, P.D.; Burgess, L.; Ceska, R.; Roth, E.; Koren, M.J.; Ballantyne, C.M.; Monsalvo, M.L.; Tsirtsonis, K.; Kim, J.B.; Scott, R.; Wasserman, S.M.; Stein, E.A. A 52-week placebo-controlled trial of evolocumab in hyper-lipidemia. N. Engl. J. Med., 2014, 370(19), 1809-1819.
[http://dx.doi.org/10.1056/NEJMoa1316222] [PMID: 24678979]

Lloyd-Jones, D.M.; Morris, P.B.; Ballantyne, C.M.; Birtcher, K.K.; Daly, D.D., Jr; DePalma, S.M.; Minissian, M.B.; Orringer, C.E.; Smith, S.C., Jr ACC expert consensus decision pathway on the role of non-statin therapies for LDL-Cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American College of Cardiology task force on clinical expert consensus docu-ments. J. Am. Coll. Cardiol., 2016, 68(1), 92-125.
[http://dx.doi.org/10.1016/j.jacc.2016.03.519] [PMID: 27046161]

Robinson, J.G.; Huijgen, R.; Ray, K.; Persons, J.; Kastelein, J.J.P.; Pencina, M.J. Determining when to add nonstatin therapy: a quantitative approach. J. Am. Coll. Cardiol., 2016, 68(22), 2412-2421.
[http://dx.doi.org/10.1016/j.jacc.2016.09.928] [PMID: 27908345]

McNutt, M.C.; Kwon, H.J.; Chen, C.; Chen, J.R.; Horton, J.D.; Lagace, T.A. Antagonism of secreted PCSK9 increases low density lipopro-tein receptor expression in HepG2 cells. J. Biol. Chem., 2009, 284(16), 10561-10570.
[http://dx.doi.org/10.1074/jbc.M808802200] [PMID: 19224862]

Shan, L.; Pang, L.; Zhang, R.; Murgolo, N.J.; Lan, H.; Hedrick, J.A. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun., 2008, 375(1), 69-73.
[http://dx.doi.org/10.1016/j.bbrc.2008.07.106] [PMID: 18675252]

Zhang, D.W.; Lagace, T.A.; Garuti, R.; Zhao, Z.; McDonald, M.; Horton, J.D.; Cohen, J.C.; Hobbs, H.H. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and in-creases degradation. J. Biol. Chem., 2007, 282(25), 18602-18612.
[http://dx.doi.org/10.1074/jbc.M702027200] [PMID: 17452316]

Benjannet, S.; Rhainds, D.; Essalmani, R.; Mayne, J.; Wickham, L.; Jin, W.; Asselin, M.C.; Hamelin, J.; Varret, M.; Allard, D.; Trillard, M.; Abifadel, M.; Tebon, A.; Attie, A.D.; Rader, D.J.; Boileau, C.; Brissette, L.; Chrétien, M.; Prat, A.; Seidah, N.G. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem., 2004, 279(47), 48865-48875.
[http://dx.doi.org/10.1074/jbc.M409699200] [PMID: 15358785]

Palmer-Smith, H.; Basak, A. Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R). Curr. Med. Chem., 2010, 17(20), 2168-2182.
[http://dx.doi.org/10.2174/092986710791299948] [PMID: 20423303]

Alghamdi, R.H.; O’Reilly, P.; Lu, C.; Gomes, J.; Lagace, T.A.; Basak, A. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153–421): Design, synthesis and biochemical evaluation. Eur. J. Med. Chem., 2015, 92, 890-907.
[http://dx.doi.org/10.1016/j.ejmech.2015.01.022] [PMID: 25679794]

Schroeder, C.I.; Swedberg, J.E.; Withka, J.M.; Rosengren, K.J.; Akcan, M.; Clayton, D.J.; Daly, N.L.; Cheneval, O.; Borzilleri, K.A.; Grif-for, M.; Stock, I.; Colless, B.; Walsh, P.; Sunderland, P.; Reyes, A.; Dullea, R.; Ammirati, M.; Liu, S.; McClure, K.F.; Tu, M.; Bhattacharya, S.K.; Liras, S.; Price, D.A.; Craik, D.J. Design and synthesis of truncated EGF-A peptides that restore LDL-R recycling in the presence of PCSK9 in vitro. Chem. Biol., 2014, 21(2), 284-294.
[http://dx.doi.org/10.1016/j.chembiol.2013.11.014] [PMID: 24440079]

Zhang, Y.; Eigenbrot, C.; Zhou, L.; Shia, S.; Li, W.; Quan, C.; Tom, J.; Moran, P.; Di Lello, P.; Skelton, N.J.; Kong-Beltran, M.; Peterson, A.; Kirchhofer, D. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J. Biol. Chem., 2014, 289(2), 942-955.
[http://dx.doi.org/10.1074/jbc.M113.514067] [PMID: 24225950]

Stucchi, M.; Grazioso, G.; Lammi, C.; Manara, S.; Zanoni, C.; Arnoldi, A.; Lesma, G.; Silvani, A. Disrupting the PCSK9/LDLR protein–protein interaction by an imidazole-based minimalist peptidomimetic. Org. Biomol. Chem., 2016, 14(41), 9736-9740.
[http://dx.doi.org/10.1039/C6OB01642A] [PMID: 27722650]

Akram, O.N.; Bernier, A.; Petrides, F.; Wong, G.; Lambert, G. Beyond LDL cholesterol, a new role for PCSK9. Arterioscler. Thromb. Vasc. Biol., 2010, 30(7), 1279-1281.
[http://dx.doi.org/10.1161/ATVBAHA.110.209007] [PMID: 20554949]

Frank-Kamenetsky, M.; Grefhorst, A.; Anderson, N.N.; Racie, T.S.; Bramlage, B.; Akinc, A.; Butler, D.; Charisse, K.; Dorkin, R.; Fan, Y.; Gamba-Vitalo, C.; Hadwiger, P.; Jayaraman, M.; John, M.; Jayaprakash, K.N.; Maier, M.; Nechev, L.; Rajeev, K.G.; Read, T.; Röhl, I.; Soutschek, J.; Tan, P.; Wong, J.; Wang, G.; Zimmermann, T.; de Fougerolles, A.; Vornlocher, H.P.; Langer, R.; Anderson, D.G.; Mano-haran, M.; Koteliansky, V.; Horton, J.D.; Fitzgerald, K. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA, 2008, 105(33), 11915-11920.
[http://dx.doi.org/10.1073/pnas.0805434105] [PMID: 18695239]

Fitzgerald, K.; Frank-Kamenetsky, M.; Shulga-Morskaya, S.; Liebow, A.; Bettencourt, B.R.; Sutherland, J.E.; Hutabarat, R.M.; Clausen, V.A.; Karsten, V.; Cehelsky, J.; Nochur, S.V.; Kotelianski, V.; Horton, J.; Mant, T.; Chiesa, J.; Ritter, J.; Munisamy, M.; Vaishnaw, A.K.; Gollob, J.A.; Simon, A. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet, 2014, 383(9911), 60-68.
[http://dx.doi.org/10.1016/S0140-6736(13)61914-5] [PMID: 24094767]

Fitzgerald, K.; White, S.; Borodovsky, A.; Bettencourt, B.R.; Strahs, A.; Clausen, V.; Wijngaard, P.; Horton, J.D.; Taubel, J.; Brooks, A.; Fernando, C.; Kauffman, R.S.; Kallend, D.; Vaishnaw, A.; Simon, A. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med., 2017, 376(1), 41-51.
[http://dx.doi.org/10.1056/NEJMoa1609243] [PMID: 27959715]

Ray, K.K.; Landmesser, U.; Leiter, L.A.; Kallend, D.; Dufour, R.; Karakas, M.; Hall, T.; Troquay, R.P.T.; Turner, T.; Visseren, F.L.J.; Wijngaard, P.; Wright, R.S.; Kastelein, J.J.P. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N. Engl. J. Med., 2017, 376(15), 1430-1440.
[http://dx.doi.org/10.1056/NEJMoa1615758] [PMID: 28306389]

Chery, J. RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J., 2016, 4(7), 35-50.
[http://dx.doi.org/10.14304/SURYA.JPR.V4N7.5] [PMID: 27570789]

Lindholm, M.W.; Elmén, J.; Fisker, N.; Hansen, H.F.; Persson, R.; Møller, M.R.; Rosenbohm, C.; Ørum, H.; Straarup, E.M.; Koch, T. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol. Ther., 2012, 20(2), 376-381.
[http://dx.doi.org/10.1038/mt.2011.260] [PMID: 22108858]

Gupta, N.; Fisker, N.; Asselin, M.C.; Lindholm, M.; Rosenbohm, C.; Ørum, H.; Elmén, J.; Seidah, N.G.; Straarup, E.M. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One, 2010, 5(5)e10682
[http://dx.doi.org/10.1371/journal.pone.0010682] [PMID: 20498851]

Galabova, G.; Brunner, S.; Winsauer, G.; Juno, C.; Wanko, B.; Mairhofer, A.; Lührs, P.; Schneeberger, A.; von Bonin, A.; Mattner, F.; Schmidt, W.; Staffler, G. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management. PLoS One, 2014, 9(12)e114469
[http://dx.doi.org/10.1371/journal.pone.0114469] [PMID: 25474576]

Crossey, E.; Amar, M.J.A.; Sampson, M.; Peabody, J.; Schiller, J.T.; Chackerian, B.; Remaley, A.T. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine, 2015, 33(43), 5747-5755.
[http://dx.doi.org/10.1016/j.vaccine.2015.09.044] [PMID: 26413878]

Govea-Alonso, D.O.; Beltrán-López, J.; Salazar-González, J.A.; Vargas-Morales, J.; Rosales-Mendoza, S. Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Rev. Vaccines, 2017, 16(4), 337-350.
[http://dx.doi.org/10.1080/14760584.2017.1258309] [PMID: 27817213]

Landlinger, C.; Pouwer, M.G.; Juno, C.; van der Hoorn, J.W.A.; Pieterman, E.J.; Jukema, J.W.; Staffler, G.; Princen, H.M.G.; Galabova, G. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atheroscle-rosis in APOE*3Leiden.CETP mice. Eur. Heart J., 2017, 38(32), 2499-2507.
[http://dx.doi.org/10.1093/eurheartj/ehx260] [PMID: 28637178]

Stein, E.A.; Raal, F.J. Update on PCSK9 inhibitors and new therapies. US Endocrinol., 2016, 12(1), 18-21.
[http://dx.doi.org/10.17925/USE.2016.12.01.18]

Stein, E.A.; Gipe, D.; Bergeron, J.; Gaudet, D.; Weiss, R.; Dufour, R.; Wu, R.; Pordy, R. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on sta-ble statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet, 2012, 380(9836), 29-36.
[http://dx.doi.org/10.1016/S0140-6736(12)60771-5] [PMID: 22633824]

McKenney, J.M.; Koren, M.J.; Kereiakes, D.J.; Hanotin, C.; Ferrand, A.C.; Stein, E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia re-ceiving ongoing stable atorvastatin therapy. J. Am. Coll. Cardiol., 2012, 59(25), 2344-2353.
[http://dx.doi.org/10.1016/j.jacc.2012.03.007] [PMID: 22463922]

Alirocumab Briefing Document: Endocrine & metabolic advisory committee meeting 2015. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM449865.pdf(Accessed February 2, 2022)

Chaudhary, R.; Garg, J.; Shah, N.; Sumner, A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J. Cardiol., 2017, 9(2), 76-91.
[http://dx.doi.org/10.4330/wjc.v9.i2.76] [PMID: 28289523]

Kosmas, C.E.; Skavdis, A.; Sourlas, A.; Papakonstantinou, E.J.; Peña Genao, E.; Echavarria Uceta, R.; Guzman, E. Safety and tolerability of PCSK9 inhibitors: Current insights. Clin. Pharmacol., 2020, 12, 191-202.
[http://dx.doi.org/10.2147/CPAA.S288831] [PMID: 33335431]

Gürgöze, M.T.; Muller-Hansma, A.H.G.; Schreuder, M.M.; Galema-Boers, A.M.H.; Boersma, E.; Roeters van Lennep, J.E. Adverse events associated with PCSK9 inhibitors: A real-world experience. Clin. Pharmacol. Ther., 2019, 105(2), 496-504.
[http://dx.doi.org/10.1002/cpt.1193] [PMID: 30053327]

van Bruggen, F.H.; Nijhuis, G.B.J.; Zuidema, S.U.; Luijendijk, H. Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review. Expert Rev. Clin. Pharmacol., 2020, 13(7), 787-796.
[http://dx.doi.org/10.1080/17512433.2020.1787832] [PMID: 32597252]

Abifadel, M.; Boileau, C.; Rabes, J.P.; Seidah, N.G.; Varret, M. Method for detecting the presence of or predisposition to autosomal dominant hypercholesterolemia U.S Patent US20077300754, 2007.

Seidah, N.G.; Labonte, P. Methods of reducing a viral infection and kits therefore. U.S. Patent US20090104209, 2009.

Mintier, G.A.; Chen, J.; Feder, J.N.; Parker, R.A.; Miao, B. Polynucleotides encoding novel pcsk9 variants. U.S. Patent WO2008105797A3, 2008.

Tan, P.; Bramlage, B.; Frank-kamenetsk, M.; Fitzgerald, K.; Akinc, A.; Kotelianski, V.E. Compositions and methods for inhibiting expression of the pcsk9 gene. U.S. Patent US20080113930A1, 2008.

Mcswiggen, J.; Jadhav, V.; Vaish, N.; Guerciolini, R.; Vargeese, C. RNA interference mediated inhibition of proprotein convertase subtilisin kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA). U.S. Patent US20070173473A1, 2007.

Khvorova, A.; Reynolds, A.; Leake, D.; Marshall, W.; Read, S.; Scaringe, S. siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). U.S. Patent US20080306015A1, 2008.

Bhanot, S.; Geary, R.S.; Mckay, R.; Monia, B.P.; Seth, P.P.; Siwkowski, A.M.; Swayze, E.E.; Wancewicz, E. Compounds and methods for modulating expression of pcsk9., European Patent EP2023939A2, 2009.

Quay, S.C.; Mcswiggen, J.; Vaish, N.K.; Ahmadian, M. Nucleic acid compounds for inhibiting pcsk9 gene exprression and uses thereof. U.S. Patent WO2008109472, 2008.

Jackson, S.M.; Walker, N.P.C.; Piper, D.E.; Shan, B.; Shen, W.; Chan, J.C.Y.; King, C.T.; Ketchem, R.R.; Mehlin, C.; Carabeo, T.A. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9). U.S. Patent WO2009026558A1, 2009.

Hedrick, J.A.; Monsma, F.J.J.; Churakova, T.; Hollenbaugh, D. Anti-pcsk9 and methods for treating lipid and cholesterol disorders. U.S. Patent WO2009055783A2, 2009.

Abdel-Meguid, S.S.; Abou-Gharbia, M.; Blass, B.; Childers, W.; Elshourbagy, N.; Ghidu, V.; Rogelio Martinez, R.; Meyers, H.; Mousa, S.A. Anti-pcsk9 compounds and methods for the treatmentand/or prevention of cardiovascular diseases. U.S. Patent WO2014150395A1, 2014.

Briner, K.; Dechristopher, B.A.; Flyer, N.A.; Golosov, A.A.; Grosche, P.; Liu, E.Y.; Mao, J.Y.C.; Monovich, L.G.; Patel, T.J.; Sanchez, C.C.; Su, L.; Yang, L.; Zheng, R. Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders. U.S. Patent US11026993B2,, 2021.

Mousa, S.A.; Elshourbagy, N.A.; Meyers, H.V.; Abdel-Meguid, S.S. Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) nano-formulation of compounds and methods of using the same. U.S. Patent US20220031665A1, 2022.